» Articles » PMID: 17006938

Leptin-mediated Neovascularization is a Prerequisite for Progression of Nonalcoholic Steatohepatitis in Rats

Abstract

Nonalcoholic steatohepatitis (NASH) may cause fibrosis, cirrhosis, and hepatocellular carcinoma (HCC); however, the exact mechanism of disease progression is not fully understood. Angiogenesis has been shown to play an important role in the progression of chronic liver disease. The aim of this study was to elucidate the role of angiogenesis in the development of liver fibrosis and hepatocarcinogenesis in NASH. Zucker rats, which naturally develop leptin receptor mutations, and their lean littermate rats were fed a choline-deficient, amino acid-defined diet. Both Zucker and littermate rats showed marked steatohepatitis and elevation of oxidative stress markers (e.g., thiobarbital acid reactive substances and 8-hydroxydeoxyguanosine). In sharp contrast, liver fibrosis, glutathione-S-transferase placental form (GST-P)-positive preneoplastic lesions, and HCC developed in littermate rats but not in Zucker rats. Hepatic neovascularization and the expression of vascular endothelial growth factor (VEGF), a potent angiogenic factor, only increased in littermate rats, almost in parallel with fibrogenesis and carcinogenesis. The CD31-immunopositive neovessels were mainly localized either along the fibrotic septa or in the GST-P-positive lesions. Our in vitro study revealed that leptin exerted a proangiogenic activity in the presence of VEGF. In conclusion, these results suggest that leptin-mediated neovascularization coordinated with VEGF plays an important role in the development of liver fibrosis and hepatocarcinogenesis in NASH.

Citing Articles

The role of liver sinusoidal endothelial cells in metabolic dysfunction-associated steatotic liver diseases and liver cancer: mechanisms and potential therapies.

Mo H, Yue P, Li Q, Tan Y, Yan X, Liu X Angiogenesis. 2025; 28(2):14.

PMID: 39899173 DOI: 10.1007/s10456-025-09969-5.


Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.

Saigo Y, Uno K, Ishigure T, Odake T, Ohta T In Vivo. 2024; 38(3):990-999.

PMID: 38688597 PMC: 11059886. DOI: 10.21873/invivo.13532.


The Interplay between Liver Sinusoidal Endothelial Cells, Platelets, and Neutrophil Extracellular Traps in the Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Minciuna I, Taru M, Procopet B, Stefanescu H J Clin Med. 2024; 13(5).

PMID: 38592258 PMC: 10932189. DOI: 10.3390/jcm13051406.


Organoid-guided precision hepatology for metabolic liver disease.

Osonoi S, Takebe T J Hepatol. 2024; 80(5):805-821.

PMID: 38237864 PMC: 11828489. DOI: 10.1016/j.jhep.2024.01.002.


Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches.

Arvanitakis K, Papadakos S, Lekakis V, Koufakis T, Lempesis I, Papantoniou E Int J Mol Sci. 2023; 24(19).

PMID: 37834153 PMC: 10572430. DOI: 10.3390/ijms241914704.